197 related articles for article (PubMed ID: 31256630)
1. Design and analysis of a clinical trial using previous trials as historical control.
Schoenfeld DA; Finkelstein DM; Macklin E; Zach N; Ennist DL; Taylor AA; Atassi N;
Clin Trials; 2019 Oct; 16(5):531-538. PubMed ID: 31256630
[TBL] [Abstract][Full Text] [Related]
2. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
Smith CL; Thomas Z; Enas N; Thorn K; Lahn M; Benhadji K; Cleverly A
Pharm Stat; 2020 May; 19(3):276-290. PubMed ID: 31903699
[TBL] [Abstract][Full Text] [Related]
3. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
Sambucini V
J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
[TBL] [Abstract][Full Text] [Related]
4. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y
Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712
[TBL] [Abstract][Full Text] [Related]
5. Sample size calculation for a proof of concept study.
Yin Y
J Biopharm Stat; 2002 May; 12(2):267-76. PubMed ID: 12413244
[TBL] [Abstract][Full Text] [Related]
6. Covariate-adjusted borrowing of historical control data in randomized clinical trials.
Han B; Zhan J; John Zhong Z; Liu D; Lindborg S
Pharm Stat; 2017 Jul; 16(4):296-308. PubMed ID: 28560815
[TBL] [Abstract][Full Text] [Related]
7. Sample size calculation for a historically controlled clinical trial with adjustment for covariates.
O'Malley AJ; Normand SL; Kuntz RE
J Biopharm Stat; 2002 May; 12(2):227-47. PubMed ID: 12413242
[TBL] [Abstract][Full Text] [Related]
8. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II clinical trials.
Jung SH; Sargent DJ
J Biopharm Stat; 2014; 24(4):802-16. PubMed ID: 24697589
[TBL] [Abstract][Full Text] [Related]
10. The inclusion of real world evidence in clinical development planning.
Martina R; Jenkins D; Bujkiewicz S; Dequen P; Abrams K;
Trials; 2018 Aug; 19(1):468. PubMed ID: 30157904
[TBL] [Abstract][Full Text] [Related]
11. Using historical control information for the design and analysis of clinical trials with overdispersed count data.
Gsteiger S; Neuenschwander B; Mercier F; Schmidli H
Stat Med; 2013 Sep; 32(21):3609-22. PubMed ID: 23722585
[TBL] [Abstract][Full Text] [Related]
12. Curtailed two-stage design for comparing two arms in randomized phase II clinical trials.
Chen CM; Chi Y; Chang HM
J Biopharm Stat; 2018; 28(5):939-950. PubMed ID: 29355457
[TBL] [Abstract][Full Text] [Related]
13. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
Taylor JM; Braun TM; Li Z
Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
[TBL] [Abstract][Full Text] [Related]
14. Sample size computation in phase II designs combining the A'Hern design and the Sargent and Goldberg design.
Neven A; Mauer M; Hasan B; Sylvester R; Collette L
J Biopharm Stat; 2020 Mar; 30(2):305-321. PubMed ID: 31331234
[TBL] [Abstract][Full Text] [Related]
15. Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial.
Ohwada S; Morita S
Pharm Stat; 2016 Sep; 15(5):420-9. PubMed ID: 27485377
[TBL] [Abstract][Full Text] [Related]
16. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach.
Cellamare M; Sambucini V
Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805
[TBL] [Abstract][Full Text] [Related]
17. Between-arm comparisons in randomized Phase II trials.
Jung SH; George SL
J Biopharm Stat; 2009; 19(3):456-68. PubMed ID: 19384688
[TBL] [Abstract][Full Text] [Related]
18. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Pond GR; Abbasi S
Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
[TBL] [Abstract][Full Text] [Related]
19. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.
Brard C; Hampson LV; Gaspar N; Le Deley MC; Le Teuff G
BMC Med Res Methodol; 2019 Apr; 19(1):85. PubMed ID: 31018832
[TBL] [Abstract][Full Text] [Related]
20. Practical Bayesian guidelines for phase IIB clinical trials.
Thall PF; Simon R
Biometrics; 1994 Jun; 50(2):337-49. PubMed ID: 7980801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
